NCT05037435View on ClinicalTrials.gov

Safety and Immunological Efficacy of the Pentavalent Rotavirus Vaccine - Rota-V-Aid™ (Live Attenuated Oral, Freeze-dried) at Healthy Adults Aged 18 to 45 Years.

PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 25, 2018

Primary Completion Date

July 27, 2018

Study Completion Date

July 27, 2018

Conditions
Rotavirus InfectionsRotavirus Vaccines
Interventions
BIOLOGICAL

The pentavalent rotavirus vaccine (live attenuated oral, freeze-dried)

Group 1 (20 participants) - received the pentavalent live vaccine to prevent rotavirus infection Single-use orally 2.5 ml (1 dose).

OTHER

Placebo

Group 2 (20 participants ) - received placebo orally once of 2.5 ml (1 dose).

Trial Locations (1)

614990

Perm State Medical University named after Academician E.A. Wagner, Perm

All Listed Sponsors
lead

Limited Liability Company Pharm Aid

OTHER

NCT05037435 - Safety and Immunological Efficacy of the Pentavalent Rotavirus Vaccine - Rota-V-Aid™ (Live Attenuated Oral, Freeze-dried) at Healthy Adults Aged 18 to 45 Years. | Biotech Hunter | Biotech Hunter